No Data
Express News | Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (Aasld) 2024 Liver Meeting
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Galectin Therapeutics Unveils Future Plans and Drug Potential
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Buy Rating Affirmed for Galectin Therapeutics Ahead of Phase 2b Interim Analysis and With Strong Cash Position
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target